Gene therapy of the central nervous system: from bench to bedside
SECTION I. GENE TRANSFER TECHNOLOGY AND REGULATORY ISSUES -- 1. Design and optimization of expression cassettes including promoter choice and regulatory lements -- 2. Identification of Novel AAV Serotypes for Use as Vectors -- 3. HSV amplicon vectors for gene delivery to the nervous system -- 4. Inf...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Dokumenttyp: | Buch/Monographie |
| Sprache: | Englisch |
| Veröffentlicht: |
Amsterdam Boston
Academic Press
2006
|
| Volumes / Articles: | Show Volumes / Articles. |
| Schlagworte: | |
| Online-Zugang: | Verlag, lizenzpflichtig: https://www.sciencedirect.com/science/book/9780123976321 Verlag, ScienceDirect, Volltext: http://www.sciencedirect.com/science/book/9780123976321 
|
| Verfasserangaben: | edited by Michael G. Kaplitt and Matthew J. During |
MARC
| LEADER | 00000cam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1648438164 | ||
| 003 | DE-627 | ||
| 005 | 20250514182418.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 091105s2006 ne |||||o 00| ||eng c | ||
| 016 | 7 | |a 573155402 |2 DE-101 | |
| 020 | |a 9780123976321 |9 978-0-12-397632-1 | ||
| 020 | |a 0123976324 |9 0-12-397632-4 | ||
| 020 | |a 0080454372 |c electronic bk. |9 0-08-045437-2 | ||
| 020 | |a 9780080454375 |c electronic bk. |9 978-0-08-045437-5 | ||
| 020 | |a 1280637927 |9 1-280-63792-7 | ||
| 020 | |a 9781280637926 |9 978-1-280-63792-6 | ||
| 035 | |a (DE-627)1648438164 | ||
| 035 | |a (DE-576)312743866 | ||
| 035 | |a (DE-599)GBV573155402 | ||
| 035 | |a (OCoLC)ocn162129568 | ||
| 035 | |a (OCoLC)162129568 | ||
| 035 | |a (OCoLC)162129568 | ||
| 035 | |a (DE-627-1)002526999 | ||
| 035 | |a (ELSEVIER)ocn162129568 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 044 | |c XA-NL | ||
| 050 | 0 | |a RC350.G45 | |
| 060 | 0 | |a WL 300 | |
| 072 | 7 | |a HEA |2 bisacsh | |
| 072 | 7 | |a MED |2 bisacsh | |
| 072 | 7 | |a HEA 039110 |2 bisacsh | |
| 072 | 7 | |a MED 056000 |2 bisacsh | |
| 072 | 7 | |a HEA 039110 |2 bisacsh | |
| 072 | 7 | |a MED 056000 |2 bisacsh | |
| 072 | 7 | |a MJN |2 bicssc | |
| 082 | 0 | |a 616.8046 | |
| 082 | 0 | |a 616.8/046 | |
| 084 | |a 32 |2 sdnb | ||
| 245 | 0 | 0 | |a Gene therapy of the central nervous system |b from bench to bedside |c edited by Michael G. Kaplitt and Matthew J. During |
| 264 | 1 | |a Amsterdam |a Boston |b Academic Press |c 2006 | |
| 300 | |a Online Ressource (xiv, 355 p.) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index. - Description based on print version record | ||
| 505 | 8 | |a Cover; Gene Therapy of the Central Nervous System: From Bench to Bedside; Contents; Contributors; Preface; Section I Gene Transfer Technology and Regulatory Issues; Design and Optimization of Expression Cassettes Including Promoter Choice and Regulatory Elements; Introduction; Design of the rAAV Cassette; Cell-Type-Specific Tropism of rAAV; Choice of Promoter; Regulatory Elements; Summary and Conclusion; Identification of Novel Adeno-Associated Virus Serotypes for Use as Vectors; Introduction; Identification and Isolation of Novel Primate AAVs; Classification of Novel Primate AAVs | |
| 505 | 8 | |a Novel AAVs as Gene Transfer VectorsConclusions; HSV Amplicon Vectors for Gene Delivery to the Nervous System; Basics of HSV-1 Amplicon; Advantages of HSV-1 Amplicon; Uses in Nervous System; Perspectives; Acknowledgments; Influence of the Immune System on Central Nervous System Gene Transfer; Adaptive Immunity and Viral Vectors; Immunology of Transgenes; Conclusion; Acknowledgments; Targeted Induction of Endogenous Neural Stem and Progenitor Cells: A New Strategy for Gene Therapy of Neurological Disease; Neural Stem and Progenitor Cells of the Human Brain | |
| 505 | 8 | |a Cell Genesis in the Adult CNS Shares Common Themes with that in other Solid OrgansNeural Progenitor Cells are widely Distributed in the Adult Human Brain; Progenitor Cells may be useful as both Engraftable and Inducible Substrates for Repair; Endogenous Progenitor Cells are Mobilized by Injury and Disease; Resident Progenitor Cells can be Mobilized Pharmacologically and Genetically; Induced Neurogenesis in the Adult Neostriatum; The Development of Glial Suppressive Strategies Enhancing Heterotopic Neurogenesis; Induced Neurogenesis as a Therapeutic Strategy in Huntington's Disease | |
| 505 | 8 | |a Progenitor Cell Targeting in Parkinson's DiseaseInduced Neurogenesis as a Restorative Strategy for the Hippocampal Atrophies; Parenchymal Glial Progenitors are Attractive Targets for Exogenous Mobilization; Transduced Neural Progenitors as Vectors for Enzymatic Repletion in the Storage Diseases; Overview; Acknowledgments; Neurosurgical Targeting, Delivery, and Infusion of Gene Therapy Agents in the Brain; Anatomical Targeting in Stereotactic Neurosurgery; Methods of Accessing the Central Nervous System; Methods for Enhancing Intracranial Gene Transfer; Conclusion | |
| 505 | 8 | |a Gene Transfer for Neurological Disease: Agencies, Policies, and Process*The Landscape of Gene Therapy; Oversight of Gene Therapy Protocols; Good Practice Requirements for Gene Therapy Protocols; Clinical Phases for Development of Biologics; Sequential Steps in Implementation of a Clinical Gene Transfer Trial; Limitations of the System; Section II Gene Therapy for Degenerative and Functional Disorders; Gene Therapy for Parkinson's Disease; Introduction; Parkinson's Disease; Current Pharmacological Therapy vs. Gene Therapy for PD; Animal Models of PD | |
| 505 | 8 | |a Strategies for Gene Therapy Intervention in PD | |
| 505 | 8 | |a SECTION I. GENE TRANSFER TECHNOLOGY AND REGULATORY ISSUES -- 1. Design and optimization of expression cassettes including promoter choice and regulatory lements -- 2. Identification of Novel AAV Serotypes for Use as Vectors -- 3. HSV amplicon vectors for gene delivery to the nervous system -- 4. Influence of the immune system on CNS gene transfer -- 5. Targeted induction of endogenous neural stem and progenitor cells: A new strategy for gene therapy of neurological disease -- 6. Neurosurgical Targeting, Delivery and Infusion of Gene Therapy Agents in the Brain -- 7. Gene Transfer for Neurological Disease: Agencies, Policies and Process -- SECTION II. GENE THERAPY FOR DEGENERATIVE AND FUNCTIONAL DISORDERS -- 8. Gene therapy for Parkinsons disease -- 9. Non human primate models for testing gene therapy for neurodegenerative disorders -- 10. Delivery of Molecular Therapeutics into the CNS and their Distribution within the Brain -- 11. Gene therapy for CNS diseases using intrabodies -- 12. Gene therapy for epilepsy -- SECTION IIII. PSYCHIATRIC AND BEHAVIORAL GENE THERAPY -- 13. Genetic manipulation of learning and memory -- 14. Psychiatric applications of viral vectors -- 15. Use of viral vectors to influencebehavior -- SECTION IV. GENE THERAPY FOR PAIN AND SPINAL CORD DISEASES -- 16. Herpes simplex vector mediated gene transfer to the peripheralnervous system for the treatment of polyneuropathy and chronic pain -- 17. Characterization of pain receptors in the spinal cord using a viral vector for spatial-temportal gene targeting -- 18. Viral vector mediated gene therapy of pain -- 19. VEGF, an angiogenic factor with neurotrophic activity, useful for treatment of ALS? -- 20. Viral Vector Axonal Uptake and Retrograde Transport: Mechanisms and Applications -- 21. Gene therapy for spinal cord injury -- V. GENE THERAPY FOR BRAIN TUMORS AND NEUROGENETIC DISEASES -- 22. Prodrug-Activation Gene Therapy -- 23. Clinical trials of gene therapy for Canavan Disease -- 24. Gene therapy for the late infantile form of Batten disease -- 25. Molecular Imaging of Gene Therapy for Neurogenetic Diseases | |
| 506 | |f Restrictions unspecified |2 star | ||
| 506 | |a Legal Deposit |e The Legal Deposit Libraries (Non-Print Works) Regulations (UK) | ||
| 520 | |a SECTION I. GENE TRANSFER TECHNOLOGY AND REGULATORY ISSUES -- 1. Design and optimization of expression cassettes including promoter choice and regulatory lements -- 2. Identification of Novel AAV Serotypes for Use as Vectors -- 3. HSV amplicon vectors for gene delivery to the nervous system -- 4. Influence of the immune system on CNS gene transfer -- 5. Targeted induction of endogenous neural stem and progenitor cells: A new strategy for gene therapy of neurological disease -- 6. Neurosurgical Targeting, Delivery and Infusion of Gene Therapy Agents in the Brain -- 7. Gene Transfer for Neurological Disease: Agencies, Policies and Process -- SECTION II. GENE THERAPY FOR DEGENERATIVE AND FUNCTIONAL DISORDERS -- 8. Gene therapy for Parkinsons disease -- 9. Non human primate models for testing gene therapy for neurodegenerative disorders -- 10. Delivery of Molecular Therapeutics into the CNS and their Distribution within the Brain -- 11. Gene therapy for CNS diseases using intrabodies -- 12. Gene therapy for epilepsy -- SECTION IIII. PSYCHIATRIC AND BEHAVIORAL GENE THERAPY -- 13. Genetic manipulation of learning and memory -- 14. Psychiatric applications of viral vectors -- 15. Use of viral vectors to influencebehavior -- SECTION IV. GENE THERAPY FOR PAIN AND SPINAL CORD DISEASES -- 16. Herpes simplex vector mediated gene transfer to the peripheralnervous system for the treatment of polyneuropathy and chronic pain -- 17. Characterization of pain receptors in the spinal cord using a viral vector for spatial-temportal gene targeting -- 18. Viral vector mediated gene therapy of pain -- 19. VEGF, an angiogenic factor with neurotrophic activity, useful for treatment of ALS? -- 20. Viral Vector Axonal Uptake and Retrograde Transport: Mechanisms and Applications -- 21. Gene therapy for spinal cord injury -- V. GENE THERAPY FOR BRAIN TUMORS AND NEUROGENETIC DISEASES -- 22. Prodrug-Activation Gene Therapy -- 23. Clinical trials of gene therapy for Canavan Disease -- 24. Gene therapy for the late infantile form of Batten disease -- 25. Molecular Imaging of Gene Therapy for Neurogenetic Diseases | ||
| 520 | |a Few areas of biomedical research provide greater opportunities for radically new therapies for devastating diseases that have evaded treatment so far than gene therapy. This is particularly true for the brain and nervous system, where gene transfer has become a key technology for basic research and has recently been translated to human therapy in several landmark clinical trials. Gene Therapy of the Central Nervous System: From Bench to Bedside represents the first definitive volume on this subject. Edited by two pioneers of neurological gene therapy, this volume contains contributions by leaders who helped create this field and are expanding the promise of gene therapy for the future of basic and clinical neuroscience. Drawing upon this extensive collective experience, this book provides clear and informative reviews on a variety of subjects of interest to anyone exploring or using gene therapy for neurobiological applications in research and clinical praxis. * Presents gene transfer technologies with particular emphases upon novel vehicles, immunological issues and the role of gene therapy in stem cells * Discusses preclinical areas that are likely to translate into clinical studies in the near future, including epilepsy, pain and amyotrophic lateral sclerosis * Includes "insider" information on technological and regulatory issues which can often limit effective translation of even the most promising idea into clinical use | ||
| 533 | |a Online-Ausg. |b [S.l.] |c Elsevier |d 2007 |e Online-Ressource |f ScienceDirect |7 |2007|||||||||| | ||
| 538 | |a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. | ||
| 540 | |a Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force | ||
| 650 | 0 | |a Nervous system |x Diseases |x Gene therapy | |
| 650 | 0 | |a Nervous system |x Diseases |x Gene therapy | |
| 650 | 0 | |a Gene therapy | |
| 650 | 2 | |a Gene Therapy | |
| 650 | 2 | |a Gene Transfer Techniques | |
| 650 | 2 | |a Genetic Vectors | |
| 650 | 2 | |a Central Nervous System Diseases |x therapy | |
| 650 | 2 | |a Central Nervous System Diseases |x genetics | |
| 650 | 2 | |a Genetic Therapy | |
| 650 | 4 | |a HEALTH & FITNESS ; Diseases ; Nervous System (incl. Brain) | |
| 650 | 4 | |a MEDICAL ; Neurology | |
| 650 | 4 | |a Syst�eme nerveux - Maladies - Th�erapie g�enique | |
| 650 | 4 | |a Th�erapie g�enique | |
| 650 | 4 | |a Gene therapy | |
| 655 | 0 | |a Electronic books | |
| 700 | 1 | |a Kaplitt, Michael G. |e Hrsg. |4 edt | |
| 776 | 1 | |z 0123976324 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Gene therapy of the central nervous system |d Amsterdam ; Boston : Academic Press, 2006 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/book/9780123976321 |m X:ELSEVIER |x Verlag |z lizenzpflichtig |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/book/9780123976321 |x Verlag |y ScienceDirect |3 Volltext |
| 889 | |w (DE-627)573155402 | ||
| 912 | |a BSZ-33-ECE | ||
| 912 | |a ZDB-33-NEU |b 1995-2006 | ||
| 912 | |a ZDB-33-NEU | ||
| 912 | |a GBV-33-EBS-MRI | ||
| 912 | |a GBV-33-EBS-ZHB | ||
| 912 | |a GBV-33-Freedom-BL | ||
| 912 | |a ZDB-33-EBS | ||
| 912 | |a ZDB-33-ESD | ||
| 935 | |h GBV |i ExPruef | ||
| 936 | s | n | |a HEA |2 bisac |
| 936 | s | n | |a MJN |2 bic |
| 936 | s | n | |a MED |2 bisac |
| 951 | |a BO | ||
| 992 | |a 20170620 | ||
| 999 | |a KXP-PPN1648438164 |e 3329047283 | ||
| BIB | |a Y | ||
| SPR | |a Y | ||
| JSO | |a {"physDesc":[{"extent":"Online Ressource (xiv, 355 p.)"}],"note":["Includes bibliographical references and index. - Description based on print version record"],"type":{"bibl":"edited-book","media":"Online-Ressource"},"language":["eng"],"recId":"1648438164","origin":[{"dateIssuedKey":"2006","publisher":"Academic Press","dateIssuedDisp":"2006","publisherPlace":"Amsterdam ; Boston"}],"title":[{"title":"Gene therapy of the central nervous system","subtitle":"from bench to bedside","title_sort":"Gene therapy of the central nervous system"}],"id":{"eki":["1648438164"],"isbn":["9780123976321","0123976324","0080454372","9780080454375","1280637927","9781280637926"]},"person":[{"role":"edt","roleDisplay":"Hrsg.","display":"Kaplitt, Michael G.","given":"Michael G.","family":"Kaplitt"}],"name":{"displayForm":["edited by Michael G. Kaplitt and Matthew J. During"]}} | ||
| SRT | |a GENETHERAP2006 | ||